Overview

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate if treatment with vernakalant hydrochloride (MK-6621) results in a greater proportion of patients with treatment-induced conversion of Atrial Fibrillation to sinus rhythm compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Cardiome Pharma
Correvio International Sarl